USA flag logo/image

An Official Website of the United States Government

SBIR Phase I:Feasibility of a minimally-invasive biomaterial therapy for heart…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
99170
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
1014429
Solicitation Year:
N/A
Solicitation Topic Code:
T10
Solicitation Number:
N/A
Small Business Information
Ventrix
3231 HILL ST SAN DIEGO, CA 92106-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: SBIR Phase I:Feasibility of a minimally-invasive biomaterial therapy for heart failure
Agency: NSF
Contract: 1014429
Award Amount: $180,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project will test the feasibility of delivering a biomaterial treatment for myocardial infarction (MI) and heart failure via catheter, thereby paving the way towards translation and commercialization. Despite recent advances in tissue engineering, heart failure post-MI continues to be the leading cause of death in the U.S. with end-stage heart failure patients still relying on donor hearts. Herein, the feasibility of delivering a regenerative matrix via catheter to the heart will be tested. The key objectives of this project are: 1) Demonstrate injection of the myocardial matrix through a catheter in a porcine MI model, and 2) Demonstrate gelation and targeted delivery of the myocardial matrix in a porcine MI model. The broader/commercial impacts of this research are the development of a new minimally invasive therapy for treating the millions of patients that suffer a MI each year, and the drastic reduction in the cost of healthcare related to MI by preventing subsequent heart failure, which is currently estimated at $37.2 billion for indirect and direct costs in 2009. This product will have significant advantages over competing technologies including: 1) minimally invasive delivery, 2) no need for donor organ or cell collection, 3) no need for immunosuppressive therapies, 4) off-the-shelf available treatment, and 5) low cost. Moreover, this will be the first injectable regenerative biomaterial product for treating the millions of patients suffering from MI and heart failure.

Principal Investigator:

Adam M. Kinsey
DPhil
4153105240
adamkinsey@ventrixheart.com

Business Contact:

Adam M. Kinsey
DPhil
4153105240
adamkinsey@ventrixheart.com
Small Business Information at Submission:

Ventrix
3231 Hill St San Diego, CA 92106

EIN/Tax ID: 264527208
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No